The Hazards of Endpoints

被引：12

作者：

Berry, Donald A. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77230 USA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2010年 / 102卷 / 18期

关键词：

CLINICAL-TRIALS; SURVIVAL;

D O I：

10.1093/jnci/djq334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1376 / 1377

页数：2

共 6 条

[1] Bayesian clinical trials [J].

Berry, DA .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (01) :27-36

[2] Bayesian survival analysis with nonproportional hazards: Metanalysis of combination pravastatin-aspirin [J].

Berry, SM ;

Berry, DA ;

Natarajan, K ;

Lin, CS ;

Hennekens, CH ;

Belder, R .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2004, 99 (465) :36-44

[3] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [J].

Broglio, Kristine R. ;

Berry, Donald A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23) :1642-1649

[4] Improved Endpoints for Cancer Immunotherapy Trials [J].

Hoos, Axel ;

Eggermont, Alexander M. M. ;

Janetzki, Sylvia ;

Hodi, F. Stephen ;

Ibrahim, Ramy ;

Anderson, Aparna ;

Humphrey, Rachel ;

Blumenstein, Brent ;

Old, Lloyd ;

Wolchok, Jedd .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (18) :1388-1397

[5]

KANTOFF P, 2010, AM SOC CLIN ONC ANN

[6] The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee [J].

Seymour, Lesley ;

Ivy, S. Percy ;

Sargent, Daniel ;

Spriggs, David ;

Baker, Laurence ;

Rubinstein, Larry ;

Ratain, Mark J. ;

Le Blanc, Michael ;

Stewart, David ;

Crowley, John ;

Groshen, Susan ;

Humphrey, Jeffrey S. ;

West, Pamela ;

Berry, Donald .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1764-1769

← 1 →